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At a Glance Commentary:  49	
Scientific Knowledge on the Subject:  50	
Pulmonary surfactant protein D (SP-D) is a soluble pattern recognition innate 51	
immune molecule involved in the clearance of pathogens, apoptotic/necrotic cells, 52	
and down-regulation of allergic inflammation. A recombinant fragment of human SP-53	
D (rfhSP-D) has been shown to be involved in pattern recognition of glycoprotein 54	
allergens derived from house dust mite (Dermatophagoides pteronyssinus)1,2 and 55	
Aspergillus fumigatus and inhibit histamine release by sensitized basophils in vitro. 56	
The effect of rfhSP-D on allergic effector cell and allergen induced T, B cell 57	
responses are yet to be evaluated. 58	
What this study adds to the field:  59	
For the first time, it has been demonstrated that rfhSP-D prevents CD23-mediated 60	
IgE-facilitated allergen presentation by B cells to CD4+ T cells and inhibits Th2 pro-61	
allergic responses. rfhSP-D also inhibits IgE production by B cells. Moreover, the 62	
effect of rfhSP-D on allergen-induced basophil activation and histamine release at 63	











Rationale: rfhSP-D has been shown to suppress house dust mite and Aspergillus 73	
fumigatus-induced allergic inflammation in murine models.  74	
Objectives: We sought to elucidate the effect of rfhSP-D on FcεRI and CD23-75	
mediated grass pollen induced allergic inflammatory responses. 76	
Methods: rfhSP-D, containing homotrimeric neck and lectin domains, was 77	
expressed in Escherichia coli BL21 (λDE3) pLysS. PBMCs and sera were obtained 78	
from grass pollen allergic individuals (n=27). The effect of rfhSP-D on basophil 79	
activation and histamine release was measured by flow cytometry. IgE-facilitated 80	
allergen binding and presentation was assessed by flow cytometry. Th2 cytokines 81	
were measured in cell culture supernatants. The effect of rfhSP-D on IgE production 82	
by B cells when stimulated with CD40L, IL-4 and IL-21 was also determined. 83	
Results:  rfhSP-D bound to Phleum pratense in a dose- and calcium-dependent 84	
manner. Allergen-induced basophil responsiveness and histamine release was 85	
inhibited in the presence of rfhSP-D, as measured by CD63, CD203c 86	
(P=0.0086,P=0.04205), and intracellular-labelled DAO (P=0.0003,P=0.0148). The 87	
binding of allergen-IgE complexes to B cells was reduced by 51%(P=0.002) in the 88	
presence of rfhSP-D. This decrease was concomitant with reduction in CD23 89	
expression on B cells (P<0.001). rfhSP-D suppressed allergen-driven CD27-90	
CD4+CRTH2+ T cell proliferation (P<0.01), IL-4 and IL-5 levels (all, P<0.01). 91	
Moreover, rfhSP-D inhibited CD40L/IL-4 and IL-21-mediated IgE production(77.12%; 92	
P=0.02) by B cells.  93	
Conclusion: For the first time, we show that rfhSP-D inhibited allergen-induced 94	
basophil responses at a single cell, level and suppressed CD23-mediated facilitated 95	
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allergen presentation and Th2 cytokine production. In addition, rfhSP-D inhibited IgE 96	
synthesis by B cells, which is also a novel observation.	97	
Keywords: allergy; innate immunity; recombinant fragment of human Surfactant 98	
protein D, allergic rhinitis, T cells, Facilitated Allergen Presentation, IgE synthesis  99	
 100	























Introduction   122	
Lung surfactant protein D (SP-D) is a soluble pattern recognition innate immune 123	
molecule involved in the clearance of pathogens, apoptotic/necrotic cells, and down- 124	
regulation of allergic inflammation.1, 2 A recombinant form of truncated human SP-D, 125	
(rfhSP-D) comprising homotrimeric  neck and C-type lectin or carbohydrate 126	
recognition domain (CRD), has been shown to be as effective as the full-length 127	
molecule in suppressing allergic parameters3, 4  in a murine model of allergic 128	
hypersensitivity to Aspergillus fumigatus allergens.5, 6 rfhSP-D can recognise 129	
glycoprotein allergens7 and inhibit histamine release by sensitized basophils in vitro 130	
in response to house dust mite (Dermatophagoides pteronyssinus)6, 8, 9 and 131	
Aspergillus fumigatus allergens. Madan et al demonstrated that therapeutic 132	
application of rfhSP-D caused a marked reduction in specific IgE and IgG1 levels, 133	
along with peripheral blood eosinophilia and pulmonary infiltration in BALB/c murine 134	
model of allergic bronchopulmonary aspergillosis (ABPA).10 In addition, rfhSP-D 135	
treatment was also found to reduce the splenic levels of pro-allergic Th2 cytokines 136	
(IL-4 and IL-5) and increase the protective Th1 cytokine level (IFN-γ). Although 137	
rfhSP-D has been shown to modulate IgE driven allergic inflammation, the exact 138	
mechanisms by which it exerts its immunomodulatory effects remain unclear.  139	
 140	
We, therefore, tested if rfhSP-D binds to grass pollen allergen (P. pratense), inhibits 141	
histamine release and activation of basophils derived from grass pollen allergic 142	
individuals. We further hypothesized that rfhSP-D can inhibit IgE-facilitated antigen 143	
presentation (FAP), which is dependent on the interaction of allergen-IgE complexes 144	
with low-affinity IgE receptor (FcεRII or CD23) on the surface of B cells. Moreover, 145	
the effect of rfhSP-D on Th2 cells and IgE synthesis from B cells was examined. 146	
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Some of the results of this study have been previously reported in the form of 147	





























Untreated well-characterized grass pollen allergic patients (SAR) (n=27) were 175	
recruited (Table I). All subjects were selected on the basis of moderate-to-severe 176	
seasonal allergic rhinitis and poor symptom control in previous years despite regular 177	
medication use. Subjects had a positive skin prick test response (wheal >5 mm) to 178	
P.pratense grass pollen extract (ALK Soluprick; ALK-Abello, Hørsholm, Denmark). 179	
The study protocol was approved by the Royal Brompton and Harefield Hospitals 180	
NHS Trust Ethics Committee. All subjects provided written informed consent.  181	
 182	
Expression and purification of rfhSP-D  183	
The recombinant fragment of human surfactant protein D molecule (rfhSP-D) was 184	
expressed in E. coli. Details of the methods are in this article’s Online Repository. 185	
The endotoxin level in the protein preparation was determined by QCL-1000 Limulus 186	
amoebocyte lysate system (Allendale, Lonza, USA). The assay was linear over a 187	
range of 0.1–1.0 EU/mL (10 EU=1ng of endotoxin), and thus found to be under 188	
1EU/mL of rfhSP-D. BS3 [Bis (sulfosuccinimidyl) suberate] cross-linking assay 189	
(Thermo Scientific, Pierce, UK) was used to confirm the trimerization of rfhSP-D.  190	
 191	
Binding of rfhSP-D to P. pratense allergen 192	
A 96-well maxisorp microtitre plate (Nunc, Thermo Fisher, Loughborough, UK) was 193	
coated overnight with 5 µg/mL Phlp allergen and left overnight at 4ºC. Plate was 194	
blocked with 1% w/v BSA in PBS for 2 hrs at room temperature. The microtitre plate 195	
was then washed 3 times with PBS + 0.05% Tween 20, and biotinylated rfhSP-D or 196	
BSA (control) was added at varying concentrations in 5 mM CaCl2. Following the 197	
addition of rfhSP-D, the plate was further incubated for 2 hrs at 37ºC and then 198	
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washed as before. HRP conjugated Streptavidin at 1 in 1000 dilution was added to 199	
each well and further incubated for 1 hr at 37˚C, followed by an additional washing 200	
step. Binding of rfhSP-D to Phlp allergen was detected by addition of o-201	
Pheneylenediamine (OPD) substrate (Sigma-Aldrich, Dorset, UK) and color was 202	
read at 415nm. Far western blotting was used to detect the binding of rfhSP-D with 203	
P. pratense extract. Details of the methods are described in the Methods section in 204	
this article’s Online Repository. 205	
 206	
Ex-vivo basophil reactivity and histamine release assay 207	
The effects of rfhSP-D on allergen-induced basophil responsiveness and histamine 208	
release at a single cell level was measured by flow cytometry.12 Details of the 209	
methods are described under the Methods section in this article’s Online Repository. 210	
Briefly, 0, 33 and 100 ng/mL of Phlp was added to heparinized whole blood obtained 211	
from grass pollen allergic patients with or without rfhSP-D (5 µg/mL) and incubated 212	
for 15 min in water bath at 37ºC. Cells were then immunostained with anti-human 213	
CD3, CD303, CD294 (CRTh2), CD203c, CD63 and CD107a (all BD Biosciences, 214	
San Jose, CA). Erythrocytes from whole blood were lysed with BD lysing solution 215	
(BD Biosciences, San Jose, CA) for 10 min at room temperature in the dark; 216	
samples were centrifuged (5 min, 200 g) and the supernatants discarded. Cells were 217	
fixed, and then permeabilized with BD Cytofix/CytopermTM (BD Biosciences, San 218	
Jose, CA). Fluorochrome-labelled DAO (BD Biosciences, San Jose, CA) was added 219	
and the cells were incubated for 30 min at 4ºC. Cells were washed and re-220	
suspended in 450 µL ice-cold fixative solution (BD Biosciences, San Jose, CA) prior 221	
to acquisition on the BD FACSCanto II flow cytometer. Analyses were performed 222	
using BD FACSDiva V6.1.1 software (BD Biosciences, San Jose, CA).  223	
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IgE-Facilitated Allergen Binding assay  224	
IgE-facilitated allergen binding to B cells was performed as previously described.13,,14 225	
CD23 enriched B cells were treated with 5 µg/mL rfhSP-D before or after allergen-226	
IgE complexes formation  in presence of 5 mM CaCl2 for 1 hr. Indicator serum (20 227	
µL) containing high concentration of grass pollen (P. pratense) specific IgE>100KU/L 228	
was pre-incubated with 5 µL allergen (5 µg/mL) at 37ºC for 1 hr to form allergen–IgE 229	
complexes. Next, 1×105 EBV-transformed B cells (5 µL) were then added to the 230	
allergen-IgE mixture and incubated for further 1 hr at 4°C. Cells were then washed 231	
and allergen-IgE complexes bound to B cells were detected using a polyclonal 232	
human anti-IgE-labelled antibody (Miltenyi Biotech, Woking, UK).  Cells were 233	
acquired by flow cytometry (BD FACS Canto II flow cytometer, BD Biosciences, San 234	
Jose, CA) (See online supplement for further details). 235	
 236	
IgE- Facilitated Antigen Presentation (FAP) 237	
CD4+CD25- T cells and B cells were enriched by magnetic isolation from 238	
peripheral blood mononuclear cells (PBMCs) obtained from grass pollen allergic 239	
individuals. Sera from grass allergic subjects (20 µL) were pre-incubated with 0, 240	
0.1, 1 and 10 µg/mL allergen (5 µL) at 37ºC for 1 hr to form allergen-IgE 241	
complexes, which were then added to autologous B cells (irradiated at 6000 242	
rads) and incubated for 18 hrs prior to co-culture with CD4+CD25- T cells for 6 243	
days.  T cell proliferation was measured by tritiated thymidine (3H) incorporation 244	
and cytokine levels were measured in the cell culture supernatants using a 245	
commercially available MagPix Milliplex kit (EMD Millipore, Heartfordshire, UK) 246	
(see the Methods section of the Online Repository). Furthermore, PBMCs 247	
obtained were immunostained with Cell Trace violet dye and incubated with 248	
grass pollen allergen (0, 1, 5, 15 µg/mL) for 7 days in presence or absence of 249	
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rfhSP-D (5 µg/mL or 10 µg/mL) and BSA (10 µg/mL) at 37ºC (5% v/v CO2). Cells 250	
were surface-stained with anti-human CD4, CD25, CD27 and CD294 (CRTH2) 251	
antibodies and intracellularly stained with anti-IL-4, IL-5 and IFN-γ antibodies 252	
(BD Biosciences, San Jose, CA). 253	
IgE secretion assay 254	
The immunomodulatory effects of rfhSP-D on IgE synthesis by B cell was 255	
assessed using PBMCs obtained from well-characterized grass pollen allergic 256	
individuals (n=10). PBMCs were stimulated with recombinant P. pratense (5 257	
µg/mL) and IL-4 (100 ng/mL) (R&D systems, Abingdon, U.K). CD40L (100 258	
ng/mL) (R&D systems, Abingdon, U.K), and IL-21 (100 ng/mL) (Prospec-Tany, 259	
USA) in the presence of rfhSP-D at 5 µg/mL and BSA at 5 µg/mL for 14 days at 260	
37ºC. Total IgE levels were quantified in the cell culture supernatants using 261	
ImmunoCAP® Total IgE Fluoro-enzyme immunoassay.  262	
Statistical analysis  263	
Within group comparisons were performed using the Wilcoxon signed-rank test. 264	
Between-group comparisons were performed using the Mann-Whitney U test. 265	
Correlation coefficients were obtained by Spearman’s method. The statistical 266	
software package used was GraphPad Prism, version 6 (GraphPad Software Inc., 267	










rfhSP-D binds to Phleum pratense allergen in a calcium and carbohydrate-276	
dependent manner 277	
Affinity purified rfhSP-D containing homotrimeric neck and CRD regions appeared as 278	
a ~20 kDa band on a 15% SDS-PAGE (Figure 1A). A dose-dependent BS3 cross-279	
linking effect on rfhSP-D trimerization was observed; BS3 induced cross-linking at the 280	
concentration of 1mM confirming trimerization of rfhSP-D in solution (Figure 1B).	281	
rfhSP-D was shown to bind to three grass pollen proteins around the region of 50, 40 282	
and 38 kDa via far western blot (Figure 1C). Optimal binding occurred at the 5 µg/mL 283	
concentration of rfhSP-D (Figure 1D). Moreover, this binding of rfhSP-D  to P. 284	
pratense allergen was calcium- and partly carbohydrate-dependent since the 285	
interaction was inhibited in the presence of 5 mM EDTA (P=0.002) and 5 mM 286	
maltose (Figure 1E). 	287	
	288	
rfhSP-D inhibits FcεRI-mediated basophil activation and histamine release  289	
Ex vivo grass pollen-induced basophil responsiveness, as measured by the expression 290	
of CD63 and CD203Cbright on CRTH2+ basophils, was inhibited by rfhSP-D (5 µg/mL) 291	
(Figure 2A). At the optimal allergen (P. pratense) concentration (33 ng/mL, 100 ng/mL), 292	
the proportion of CD63+CRTH2+ and CD203cbrightCRTH2+ basophils was significantly 293	
higher in absence of rfhSP-D and decreased in presence of rfhSP-D  (5 µg/mL) 294	
(P=0.0086, P=0.0205) (Figure 2A). Fluorochrome labelled-DAO was used to detect 295	
intracellular histamine in presence and absence of rfhSP-D following basophils ex-vivo 296	
allergen stimulation. The proportions of DAO-CD63+ and DAO-CD203cbright basophils 297	
were significantly increased following ex-vivo grass pollen allergen stimulation in a 298	
dose-dependent manner. This increase in the proportions of DAO-CD63+ and DAO-299	
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CD203cbright basophils was inhibited when basophils were exposed to rfhSP-D (5 300	
µg/mL) at 33 and 100 ng/mL (Figure 2B, (P=0.0003, P=0.0148)).  The proportions of 301	
DAO-CD63+ and DAO-CD203cbright basophils were lower following IgE mediated cross-302	
linking of FcεRI on basophils (Figure 2C and 2D) in presence of rfhSP-D (5 µg/mL) 303	
(P=0.0262, P=0.034). 304	
 305	
rfhSP-D inhibits binding of allergen-IgE complexes to B-cells  306	
Using an in vitro functional assay of IgE-facilitated antigen presentation (IgE-307	
FAP),13,15 we assessed whether rfhSP-D would inhibit co-operative binding of 308	
allergen-IgE complexes to CD23 on the surface of B cells (Figure 3A and 3C). 309	
Allergen-IgE complexes binding to B cells were decreased in a dose-dependent 310	
manner in the presence of rfhSP-D and was optimal at 10 µg/mL (P=0.0001) (Figure 311	
3B). This reduction in allergen-IgE binding to B cells coincided with the reduction of 312	
CD23 expression on B cells when cells were pre-treated with rfhSP-D (spearman 313	
rank r=-0.383; P<0.001) (Figure 3D).  However, rfhSP-D did not have an effect on 314	
preformed  allergen-IgE complexes binding to CD23 on the surface of B cells (see 315	
Online Repository Figure E2, Online Repository methods). 316	
 317	
CD23-mediated and IgE-facilitated allergen presentation by B cells to T cells is 318	
inhibited by rfhSPD 319	
To determine whether rfhSP-D could inhibit IgE-facilitated allergen presentation and 320	
CD4+CD25- T effector cell activation, autologous B cells were pre-incubated with 0, 321	
0.1, 1 or 10 µg/mL of grass pollen allergen, IgE-containing serum and rfhSP-D (0, 5 322	
or 10 µg/mL). CD4+CD25- T effector cells proliferated in an allergen dose-dependent 323	
manner (Figure 3E). rfhSP-D inhibited T effector cell proliferation at 5 (P=0.0002) 324	
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and 10 ng/mL (P=0.007). Similarly, IL-4+CD4+CD25- (P=0.007, P=0.002) and IL-325	
5+CD4+CD25- (P=0.0033, P=0.0003) T cells proliferated in an allergen dose-326	
dependent manner (Figure 3F and 3G).  327	
 328	
rfhSP-D inhibits grass pollen-driven Th2 cell responses and promotes Th1 329	
responses     330	
PBMCs, obtained from grass pollen allergic individuals with seasonal allergic rhinitis, 331	
were stimulated with P. pratense extract (0, 1, 5 and 15 µg/mL) and exposed to 332	
varying concentrations of rfhSP-D (0, 5 and 10 µg/mL) for 6 days. rfhSP-D inhibited 333	
allergen-driven CD4+CD27-CRTH2+ T cell proliferation in a dose-dependent manner 334	
when cells were stimulated with 1 µg/mL (5 µg/mL rfhSP-D , P<0.0006; 10 µg/mL 335	
rfhSP-D , P<0.0006), 5 µg/mL (5 µg/mL rfhSP-D , ns; 10 µg/mL rfhSP-D , P<0.048) 336	
and 15 µg/mL (5 µg/mL rfhSP-D , P<0.0006; 10 µg/mL rfhSP-D , P<0.0006) of P. 337	
pratense (Figure 4A and Table E1 in this article online repository). In addition to T 338	
cell proliferation, an allergen dose-dependent increase in the proportion of IL-4 and 339	
IL-5 producing CD4+CD27-CRTH2+ T cells was also observed. IL-4+ and IL-5+ 340	
CD4+CD27-CRTH2+ T cells were significantly increased at 1 µg/mL (P<0.007), 5 341	
µg/mL (P<0.007) and 15 µg/mL (P=0.007) when compared to 0 µg/mL of P. 342	
pratense. This increase in the proportion of IL-4+ and IL-5+ CD4+CD27-CRTH2+ T 343	
cells was significantly reduced by rfhSP-D in a dose-dependent manner (Figure 4B 344	
and 4C). Conversely, rfhSP-D induced allergen-driven IFN-γ+CD4+CD27-CRTH2+ T 345	
cell proliferation when stimulated with 1 µg/mL (5 µg/mL rfhSP-D , P=0.031; 10 346	
µg/mL rfhSP-D , P<0.007), 5 µg/mL (5 µg/mL rfhSP-D , P<0.007; 10 µg/mL rfhSP-D , 347	
P<0.007) and 15 µg/mL (5µg/mL rfhSP-D , P<0.007; 10 µg/mL rfhSP-D , P<0.007) of 348	
P. pratense (Figure 4D). 349	
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rfhSP-D modulates P.pratense-driven Th2 responses 	350	
 We also studied the effect of rfhSP-D on P. pratense driven T cell proliferation via 351	
3H-Thymidine incorporation assay. Pre-treatment of PBMCs with rfhSP-D resulted in 352	
~94% (P<0.0001) and 93% (P<0.0001) suppression of allergen-driven T cells 353	
proliferation when 5 µg/mL and 10 µg/mL rfhSP-D was used (see Figure E1 in this 354	
article online repository). The ability of rfhSP-D to inhibit allergen driven pro-allergic 355	
Th2 cytokine responses was also assessed using multiplex cytokine analysis. rfhSP-356	
D (5 µg/mL) suppressed IL-4 (13.41%; P=0.0019), IL-5 (99.31%; P<0.0001), IL-9 357	
(99.82%; P<0.0001), IL-13 (99.48%; P<0.0001), IL-6 (64.70%; P=0.0286) and IL-17a 358	
(89.74 %; P=0.0286) levels (Figure 4E). rfhSP-D also suppressed Eotaxin (36.33%; 359	
P<0.0001) and MDC (93.78%; P<0.0001) levels, whereas no effect of rfhSP-D was 360	
observed on the secretion levels of CXCL8 (P=0.7808) and RANTES (P=0.2150) 361	
(Figure 4F). 362	
 363	
Effect of rfhSP-D on IgE production by B cells 364	
The immunomodulatory effect of rfhSP-D on IgE synthesis was determined by 365	
stimulating PBMCs obtained from allergic individuals with grass pollen allergen in the 366	
presence of CD40L, IL-4 and IL-21. CD40L and IL-4 induced IgE production, while 367	
IL-21 further enhanced IgE synthesis from B cells in PBMCs cultures (60.97%: 368	
P=0.3104). Remarkably, rfhSP-D inhibited CD40L/IL-4- and IL-21-induced total IgE 369	








In this study, we have shown, for the first time, that a recombinant fragment of 376	
human surfactant protein D (rfhSP-D) inhibits grass pollen allergen-induced basophil 377	
activation and suppresses histamine release at a single cell level. Furthermore, 378	
rfhSP-D prevents CD23-mediated IgE-facilitated allergen presentation by B cells to 379	
CD4+ T cells and inhibits pro-allergic Th2 immune responses. Furthermore, rfhSP-D 380	
inhibits IgE production by B cells in vitro when stimulated with CD40L, IL-4 and IL-381	
21.  382	
 383	
rfhSP-D has been shown to have therapeutic effects in murine models of allergy.6 384	
These include lowering of IgE levels, suppression of peripheral and pulmonary 385	
eosinophilia, and Th2 to Th1 cytokine polarization.6, 16 However, this effect has only 386	
been shown in mice but not in humans.6 rfhSP-D has previously been shown to have 387	
various immunomodulatory properties.2, 4, 16, 17, 18 However, the underlying 388	
mechanisms by which rfhSP-D suppresses allergic inflammatory response have not 389	
been fully determined. In vitro studies showed that rfhSP-D bound to P. pratense 390	
allergen in a dose-, calcium- and carbohydrate-dependent manner. Far western blot 391	
revealed that rfhSP-D bound three proteins in the P. pratense extract which were 392	
~50kDa, 40kDa and 38kDa in size. The interaction of rfhSP-D with the carbohydrate 393	
residues on the P. pratense allergens via CRDs is consistent with the previous 394	
reports.19, 20, 21  395	
 396	
rfhSP-D was able to inhibit ex vivo allergen-induced basophil activation, as 397	
measured by CD63 and CD203c expression. We demonstrated suppression of 398	
histamine release at the single cell level, using a novel method which utilizes 399	
fluorochrome-labelled DAO.12 In the mid-1990s, an enzyme-affinity-gold method 400	
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based on the affinity of diamine oxidase (DAO) for its substrate, histamine, was used 401	
to localize intracellular histamine in mast cells.22  Subsequently, a DAO-colloidal 402	
gold-based technique has also been used to localize histamine within basophils.23 403	
We used multi-parametric gating strategy to measure intracellularly labelled DAO at 404	
the single-cell level. This multi-parametric combined labeling of DAO and CD 405	
markers provides not only activation status at the single-cell level but also functional, 406	
allergen-specific basophil read-out. In a novel approach, we combined detection of 407	
two basophil surface markers as well as intracellular DAO. We show here that rfhSP-408	
D inhibits allergen-induced basophil activation and suppresses histamine release. 409	
 410	
The immunomodulatory effect of rfhSP-D on IgE-facilitated antigen presentation was 411	
also examined, using an IgE-Facilitated Allergen Binding (IgE-FAB) assay. This 412	
assay was used to examine allergen-IgE complexes binding to CD23 enriched B 413	
cells that were pre-treated with 5 µg/mL of rfhSP-D. Sera obtained from well-414	
characterized grass pollen allergic patients with seasonal allergic rhinitis were used 415	
as a source of specific IgE.24 This assay represents an in vitro model of facilitated 416	
allergen presentation, where allergen-IgE complexes are incubated with a B cell line. 417	
The complexes, bound to CD23 on the surface of B cells, are then detected by flow 418	
cytometry. Although the read-out from this assay does not examine directly the 419	
antigen presenting capacity of B cells to T cells, this assay, however, has been 420	
shown to serve as a representative of this process.25 rfhSP-D suppressed the co-421	
operative binding of allergen-IgE complexes to B cells by up to 51% when CD23-422	
enriched B cells were pre-treated with 10 µg/mL rfhSP-D. This is an interesting and 423	
novel finding since it has been previously shown that serum level of soluble CD23 424	
(sCD23) correlates with allergic seasonal symptoms.26, 32 Additional studies also 425	
suggest the involvement of CD23 in IgE regulation.27    Moreover,  when preformed 426	
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complexes were exposed to rfhSP-D, the binding of allergen-IgE complexes to CD23 427	
on the surface of B cells was unaffected.  This finding suggests that rfhSP-D does 428	
block IgE sites that are required for binding to CD23. This is, therefore, the first 429	
study, which establishes a link between rfhSP-D and CD23, suggesting that an 430	
interference with facilitated antigen presentation by rfhSP-D is dependent on the 431	
interaction between rfhSP-D and CD23 (FcεRII). A reduction in CD23 expression will 432	
inhibit facilitated antigen presentation, and hence, allergen-induced Th2 cytokine 433	
response. This interaction between rfhSP-D and CD23 requires further 434	
characterization in order to better understand how rfhSP-D can play a role in IgE 435	
regulation. It appears that rfhSP-D may prevent the worsening of allergic symptoms 436	
occurring through CD23/IgE-mediated antigen presentation by B-cells.28 437	
 438	
A link between an increased allergen specific IgE level found in the serum of atopic 439	
patients and a pronounced allergen-driven T cell proliferation has also been 440	
established in vitro.29 Thus, we examined the effect of rfhSP-D on the antigen 441	
presentation and proliferation of CD4+ T cells since the results from IgE FAB assay 442	
can correlate with reduction in T lymphocyte proliferation.27 We compared the 443	
proliferation of untreated P. pratense stimulated PBMCs with those pre-treated with 444	
rfhSP-D prior to allergen stimulation. We used PBMCs obtained from 10 well-445	
characterized atopic patients who were highly sensitized to P. pratense allergen. 446	
Pre-treatment of PBMCs with rfhSP-D showed suppression of allergen induced T-447	
cell proliferation at 5 as well as 10 µg/mL concentration of rfhSP-D. The anti-448	
proliferative effect of rfhSP-D on P. pratense-stimulated PBMCs in this study further 449	
conforms to an earlier study,9, 30 where the inhibitory effect of rfhSP-D was shown on 450	




The ability of rfhSP-D to inhibit allergen driven pro-inflammatory Th2 cytokine and 453	
chemokine production was also examined. rfhSP-D inhibited the production of pro-454	
inflammatory Th2 cytokines such as IL-4, IL-5, IL-9 and IL-13, in addition to 455	
suppressing IL-6 and IL-17a.  The effect of rfhSP-D on allergy-related chemokines 456	
was also examined, since chemokines facilitate infiltration at the site of 457	
inflammation.31 rfhSP-D was found to suppress the production of Eotaxin and MDC; 458	
however, no effect of rfhSP-D was observed in the case of CXCL8 and RANTES 459	
levels whereas IFN-γ production was increased in presence of both 5 µg/mL and 10 460	
µg/mL of rfhSP-D. Thus, rfhSP-D caused inhibition of chemokine and up-regulation 461	
of Th1 cytokine production, which would lead to decreased cellular infiltration. 462	
 463	
A novel function of rfhSP-D being reported here is its clear suppressive effect on IgE 464	
synthesis. This was shown by co-incubating the PBMCs isolated from well-465	
characterized atopic individuals with rfhSP-D for 14 days in the presence of B-cell 466	
switch factors, IL-4, CD40L along with IL-21. IL-21 was used in this assay since it 467	
has been previously shown to enhance IL-4 mediated IgE production by isolated 468	
human B cells.22 This data lends further support to our hypothesis that rfhSP-D can 469	
modulate allergic inflammation by its ability to suppress IgE biosynthesis. The 470	
mechanism of these effects needs to be further explored by assessing whether 471	
rfhSP-D can interact with CD21 as well as membrane-bound IgE. 472	
 473	
In summary, we have shown that rfhSP-D can interfere with IgE-facilitated antigen 474	
presentation, which represents a novel mechanism by which rfhSP-D suppresses 475	
pro-inflammatory Th2 lymphocyte-driven allergic inflammation and IgE production, 476	
and enhances secretion of Th1 cytokine production. However, further clinical studies 477	
20	
	
are required to establish the role of rfhSP-D as a novel immunomodulator for 478	
suppressing allergic inflammatory response. 479	
 480	
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   (n=27)  





Age (mean, range) 
 
29 (23:64)  
Allergen Grass Specific IgE (mean, SD) 33.9 ± 28.7  
Total IgE (mean, SD) 
 
387.1 ± 362.1  
Allergen skin prick test (mm2) (mean, SD) 7 (3.95)  
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Figure 1. Purification of recombinant fragment of human SP-D (rfhSP-D) and 496	
characterization of its binding to P. pratense extract (A) 15% v/v SDS-PAGE 497	
showing purified rfhSP-D protein at ~20 kDa. (B) Trimerization of rfhSP-D was 498	
achieved at 1mM concentration of BS
3
 (Bis[sulfosuccinimidyl] suberate) cross-linking 499	
agent. (C) Far western blot showing that rfhSP-D binds to three P. pratense proteins 500	
(50kDa, 40kDa and 38kDa). Lane (PM): protein marker, lane 2; the P. pratense 501	
extract, lane 3; western blot. (D) rfhSP-D binds to P. pratense extract. (E) The 502	
binding of rfhSP-D to P. pratense extract is calcium and carbohydrate-dependent and 503	
is inhibited by 5mM EDTA and 5mM Maltose. Data are presented as median 504	
(Interquartile ranges) and are representative of 5-7 independent experiments. 505	
Figure 2: rfhSP-D suppresses grass pollen allergen-driven CRTh2
+
 basophil 506	









 and CD203cbright 508	
CRTh2
+
 basophils from SAR patients (n=9) stimulated with P. pratense were 509	
suppressed in presence of rfhSP-D (5 µg/mL). (B) Representative FACS plot 510	
showing histamine suppression (DAO) in presence of rfhSP-D using intracellularly 511	









release was suppressed by 5 µg/mL of rfhSP-D. (C) & (D) rfhSP-D suppressed 513	
basophil activation and histamine release, as measured by intracellularly labelled 514	
DAO stimulated with anti-IgE (100 ng/mL). Data are expressed as medians 515	
(interquartile ranges) *P<0.05. 516	
Figure 3: Inhibition of IgE-Facilitated allergen binding and presentation by 517	
rfhSP-D.  The effect of rfhSP-D on co-operative binding of allergen-IgE complexes to 518	
CD23+ B cells was assessed on grass pollen allergic (n=10) patients. Sera were 519	
22	
	
incubated with 1 µg/mL P. pratense in presence of rfhSP-D (5 and 10 µg/mL) and 520	
BSA (10 µg/mL). (A) Representative FACS plot illustrating inhibition of allergen-IgE 521	
complex binding. (B) Dose-dependent inhibition of allergen IgE complex binding to B 522	
cells. (C) Representative FACS plot illustrating inhibition of CD23 binding. (D) 523	


















T cells (n=9). Data is expressed as medians (interquartile ranges). 526	
Between group analyses Mann-Whitney test was used and within group analysis 527	
Wilcoxon sign rank test was used. *P<0.05, **P<0.01 and ***P<0.001.  528	
Figure 4. rfhSP-D suppresses P. pratense stimulated T cell proliferative 529	
responses. PBMCs from grass pollen allergic patients (n=9) were stimulated with P. 530	
pratense (0, 1, 5 and 15 µg/mL), and then exposed to 0, 5 or 10 µg/mL of SP-D and 531	
10 µg/mL BSA as a control. CD4+T cell proliferation was measured by flow cytometry 532	
using Cell Trace violet CD27-CD4+CRTH2+ T cells. (A) rfhSP-D suppresses CD4+T 533	














 T Cells increased in presence of 5 and 10 µg/mL rfhSP-D. Data are 536	
expressed as medians (interquartile ranges). Between group analyses Mann-537	
Whitney U test was used and within group analysis Wilcoxon sign rank test was 538	
used: *P<0.05, **P <0.001, ***P <0.0001. (E) and (F) Cell culture supernatant was 539	
collected and secreted cytokines and chemokines were measured. All data are 540	
shown as mean (±SEM). P values were determined by Wilcoxon sign-rank test 541	
where *P<0.05, **P<0.01 and ***P<0.001 respectively. 542	
Figure 5. rfhSP-D inhibits IgE production from B cells in PBMCs culture. 543	
PBMCs obtained from allergic individuals (n=10) were stimulated with grass pollen 544	
23	
	
allergen in the presence of IL-4, CD40L and IL-21 for 14 days. Total IgE production 545	
from B cells was measured in the cell culture supernatants by ImmunoCAP assay in 546	
presence of rfhSP-D and BSA (5 µg/mL). All data are shown as median (Interquartile 547	
range). P values were determined by Wilcoxon sign-rank test where **represent 548	
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